-

ValGenesis to Join Industry Peers at 2026 ISPE San Francisco Vendor Night

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis Inc., the global leader in enterprise digital validation lifecycle management, will attend the 33rd Annual ISPE San Francisco Vendor Night on March 19, 2026, at Oracle Park in San Francisco.

Vendor Night is one of the Bay Area’s largest gatherings for professionals across the biotechnology, pharmaceutical, and medical device manufacturing sectors, drawing nearly 2,000 attendees, including engineers, consultants, government agencies, and academic partners.

ValGenesis executives will be on-site to connect with peers and discuss emerging trends and evolving challenges across the life sciences sector.

“Vendor Night is more than a networking event,” said David Medina, chief marketing officer at ValGenesis. “It creates space for open dialogue about the challenges facing regulated manufacturing and the technologies that are helping life sciences organizations adapt and grow.”

ValGenesis is the developer of the industry’s first AI-enabled digital platform for process design, CQV, and ongoing verification across the life sciences. Smart GxP™ helps regulated organizations execute GxP workflows with built-in compliance and real-time insights—ensuring quality, reducing risk, and accelerating the delivery of high-quality products to market.

Attendees are invited to stop by Table No. 55 to meet the ValGenesis leadership team and learn more about AI-enabled digital validation and lifecycle management.

About ValGenesis Inc.

ValGenesis, Inc. is the global leader in enterprise digital validation. Serving the life sciences industry for nearly two decades, ValGenesis enables companies to digitize their commissioning, qualification, and validation processes through its AI-enabled ValGenesis Smart GxP™ platform, which includes solutions for risk management, cleaning validation, continued process verification, and CMC development. ValGenesis helps customers worldwide reduce costs, improve compliance, and accelerate innovation. For more information, visit www.valgenesis.com.

Contacts

Further information
Althea D'Sylva, ValGenesis Communications, +1 510-445-0505 Ex.1026 althea.dsylva@valgenesis.com

ValGenesis Inc.


Release Versions

Contacts

Further information
Althea D'Sylva, ValGenesis Communications, +1 510-445-0505 Ex.1026 althea.dsylva@valgenesis.com

Social Media Profiles
More News From ValGenesis Inc.

ValGenesis Appoints David Horn as President 

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis, the global leader in digital validation and lifecycle management solutions for the life sciences industry, today announced the appointment of David Horn as president, effective Oct. 5, 2026.Horn joins ValGenesis as the company expands its Smart GxP™ platform and VAL™ (ValGenesis AI) capabilities. As president, he will focus on strengthening the company’s financial and operating foundation, supporting global growth, and expanding relationships wit...

ValGenesis to Bring Real-World AI-Assisted Validation Insights to KENX Europe 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis will share real-world AI-assisted validation insights from customer pilots and production deployments at KENX Europe 2026....

Eugia Pharmaceuticals Goes Live with ValGenesis to Modernize CSV

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis, Inc., the leader in enterprise digital validation, announced that Eugia Pharmaceuticals, a global specialty pharmaceutical company, has gone live with ValGenesis to modernize computer system validation (CSV) processes across its sites in India. The deployment will help enhance compliance, improve operational efficiency, and support growth. Hyderabad-based Eugia Pharma, a subsidiary of Aurobindo Pharma, develops and markets complex generics. The...
Back to Newsroom